October 14, 2015 Isarna Therapeutics and Autotelic Signed Asset Sale and Purchase Agreement for Trabedersen June 10, 2015 FDA Awards Isarna Orphan Drug Designation for ISTH0036 to Improve Glaucoma Treatment Outcome May 21, 2015 Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma May 11, 2015 Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma April 16, 2015 Isarna Initiates First-in-Human Phase I Trial for ISTH0036 to Treat Advanced Glaucoma January 08, 2015 Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology First-in-human Study in Advanced-stage Glaucoma to Begin in 1H2015
October 14, 2015 Isarna Therapeutics and Autotelic Signed Asset Sale and Purchase Agreement for Trabedersen
June 10, 2015 FDA Awards Isarna Orphan Drug Designation for ISTH0036 to Improve Glaucoma Treatment Outcome
May 21, 2015 Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma
May 11, 2015 Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma
January 08, 2015 Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology First-in-human Study in Advanced-stage Glaucoma to Begin in 1H2015
